|
|
IL-12-MOP |
|
Vaxjo ID |
164 |
|
Vaccine Adjuvant Name |
IL-12-MOP |
|
Alternative Names |
CTX-1796 |
|
Adjuvant VO ID |
VO_0005509
|
|
Description |
Nucleic acid vaccine adjuvant that targets on cytokine receptor to induce a Th1-based response |
|
Stage of Development |
Research |
|
Location Licensed |
US (Combined Therapeutics Boston, MA) |
|
Host Species for Testing |
3 |
|
Storage |
-80C |
|
Function |
Promotes antibody affinity maturation |
| References |
(Micol, 2024): Vaccine Adjuvant Compendium [https://vac.niaid.nih.gov/view?id=100]
Brook et al., 2024: Brook B, Duval V, Barman S, Speciner L, Sweitzer C, Khanmohammed A, Menon M, Foster K, Ghosh P, Abedi K, Koster J, Nanishi E, Baden LR, Levy O, VanCott T, Micol R, Dowling DJ. Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70. Science translational medicine. 2024; 16(757); eadm8451. [PubMed: 39047117].
|
|
